News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Odyssey Thera, Inc. Granted U.S. Patent for Novel GPCR Assay Strategy



2/12/2009 10:40:34 AM

Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.

SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-Coupled Receptors and their Signaling Pathways." The patent broadly covers methods for screening compounds and for identifying drug leads based on their ability to activate, inhibit or otherwise modulate G-protein-coupled receptors and the diverse signaling pathways linked to these receptors.

"This patent further extends and strengthens our deep patent estate in drug discovery and development technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "GPCRs are among the most valued targets for drug discovery, and our proprietary technologies enable GPCR-directed drug discovery in a native biological context. The fluorescence-based assays described in this patent are the only available strategy for capturing GPCR activities, including responses of hetero-dimeric GPCR complexes and diverse downstream effector proteins, in living human cells. These powerful new tools are essential in our search for more effective therapies for cancer and other un-met medical needs."

This is the thirteenth patent issued to Odyssey Thera, and solidifies its leadership position in cellular assay and drug discovery technologies. The inventions covered by this patent (U.S. Patent No. 7,488,583) were made by Odyssey Thera scientists.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for oncology and other chronic diseases. Odyssey Thera's pathway-based approach centers on its proprietary protein-fragment complementation assay (PCA) technology, as well as the considerable body of trade secrets it has developed in screening technologies and the understanding of complex cellular biochemical networks.

To learn more about Odyssey Thera, please visit www.odysseythera.com.

CONTACT: John Westwick of Odyssey Thera, Inc., +1-925-242-5011,
jwestwick@odysseythera.com

Web site: http://www.odysseythera.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES